News for Lyra Therapeutics, Inc. (LYRA)

Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the Company continues to

**media[566101]**

Significant Reduction in Holdings On December 31, 2024, Citadel Advisors LLC (Trades, Portfolio) executed a substantial reduction in its holdings of Lyra Therap

Lyra Therapeutics (LYRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of 21.74% and 51.25%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Cash Position: Cash, cash equivalents, and short-term investments totaled $51.6 million as of September 30, 2024, providing sufficient funding into Q1 2026.Res

-- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the...

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of 14.71% and 40.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

We recently compiled a list of the 10 Best Penny Stocks to Buy Under $1. In this article, we are going to take a look at where Lyra Therapeutics, Inc.

WATERTOWN, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced that it is advancing...

Loading... Loading... U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up ...

Loading... Loading... U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday. The Dow traded up 0....

/PRNewswire/ -- The "Transmucosal Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key...

Lyra Therapeutics has lost almost 90% of its value since its IPO in 2020. Click here to see why LYRA stock is a Buy.

Read Analyzing Lyra Therapeutics (NASDAQ:LYRA) and Adynxx (OTCMKTS:ADYX) at ETF Daily News

Read Analysts’ New Coverage for May 24th (AAMC, AAU, ACU, ADXS, ALDX, APLD, AUMN, AZN, CFTLF, CRBP) at ETF Daily News

Gainers

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...